ME/CFS Science @mecfsscience.org · 03/04/202612) Otherwise, the number of adverse events seems low and similar in the groups, so I don't think this was a major issue in the trial. There was no mortality, and around 4-5% in each group had ‘Serious Adverse Events’. 160
ME/CFS Science @mecfsscience.org · 03/04/202613) Overall, this seems like pretty convincing evidence that Paxlovid doesn’t work to treat Long Covid symptoms such as PEM, cognitive dysfunction, or orthostatic intolerance. 1112
ME/CFS Science @mecfsscience.org · 03/04/202614) RECOVER-VITAL is by far the biggest trial I have ever summarized or analyzed in ME/CFS or Long Covid. The results haven’t been published in a journal yet, they were became available on the trial registration on 27 March 2026. 1120
